New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
13:25 EDTOMEDOncoMed pullback a buying opportunity, says Piper Jaffray
Piper Jaffray believes the pullback in shares of OncoMed provides an attractive entry point into the name ahead of additional clinical data readouts in June. The reiterates an Overweight rating on the stock with a $48 price target.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
06:35 EDTOMEDOncoMed's Demcizumab shows positive Phase 1b clinical trial results
OncoMed presented new data from the Phase 1b clinical trial of demcizumab in patients with first-line advanced non-small cell lung cancer at the European Lung Cancer Conference. Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenesis and potential immune modulatory properties. Of 40 patients evaluable for efficacy, the overall RECIST response rate was 50% and an additional 15 patients had a best response of stable disease, yielding a clinical benefit rate of 88%. Median progression-free survival was 5.3 months and 5.8 months for the continuous and truncated cohorts, respectively. Prolonged PFS and OS were observed for a subset of patients treated with continuous demcizumab. A randomized Phase 2 trial of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC has been initiated and is enrolling subjects in Europe, Australia, and the United States.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use